Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 13,931 calls trading, 1.4x expected, and implied vol increasing over 13 ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage ...

Around the middle of February, shares of Recursion Pharmaceuticals bounded higher after the company reported phase 2 results ...

Recursion is currently generating limited revenue through partnerships with larger pharmaceutical leaders like Merck and ...

Explore why Recursion Pharmaceuticals' AI-driven drug discovery faces challenges in revenue growth, governance, and investor ...

Shares of Nvidia-backed Recursion Pharmaceuticals Inc. (RXRX) ended Friday lower, extending weekly losses past 21% after missing Wall Street estimates on both revenue and profit in its latest ...

Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future revenue, according to Needham.

Recursion Pharmaceuticals (NasdaqGS:RXRX) recently announced a $500 million Follow-on Equity Offering and revealed mixed earnings results for Q4 2024, which showed declining quarterly sales and ...

The Gothic Recursion collection may seem like original designs from Marvel Rivals, but Black Panther's newest skin has comic ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage biotech company, which is a pioneer in using artificial intelligence ...